April 5, 2012
Ajinomoto Pharmaceuticals announced on April 3 that the company has entered into a license agreement with Albireo AB of Sweden for exclusive rights to develop and commercialize elobixibat, a treatment for chronic constipation (CC)/irritable bowel syndrome with constipation (IBS-C) discovered...read more